Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT05502237 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05502237
- Sponsor
- Gilead Sciences
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-12
- Primary completion
- 2028-06-01
- Enrollment
- 1021
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.